Ngā hua rapu - Nathan Gossai
- E whakaatu ana i te 1 - 5 hua o te 5
-
1
Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia mā Amy K. Keating, Nathan Gossai, Christine L. Phillips, Kelly W. Maloney, Kristen Campbell, Andrew Doan, Deepa Bhojwani, Michael J. Burke, Michael R. Verneris
I whakaputaina 2019Artigo -
2
Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children’s Oncology Group report mā Nathan Gossai, Meenakshi Devidas, Zhiguo Chen, Brent L. Wood, Patrick A. Zweidler‐McKay, Karen R. Rabin, Mignon L. Loh, Elizabeth A. Raetz, Naomi J. Winick, Michael J. Burke, Andrew J. Carroll, Natia Esiashvili, Nyla A. Heerema, William L. Carroll, Stephen P. Hunger, Kimberly P. Dunsmore, Stuart S. Winter, David T. Teachey
I whakaputaina 2023Artigo -
3
More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling mā Peter Bader, Emilia Salzmann‐Manrique, Adriana Balduzzi, Jean‐Hugues Dalle, Ann E. Woolfrey, Merav Bar, Michael R. Verneris, Michael J. Borowitz, Nirali N. Shah, Nathan Gossai, Peter J. Shaw, Allen Chen, Kirk R. Schultz, Hermann Kreyenberg, Lucia Di Maio, Giovanni Cazzaniga, Cornelia Eckert, Vincent H. J. van der Velden, Rosemary Sutton, Arjan C. Lankester, Christina Peters, Thomas Klingebiel, André Willasch, Stephan A. Grupp, Michael A. Pulsipher
I whakaputaina 2019Artigo -
4
Decitabine and vorinostat with <scp>FLAG</scp> chemotherapy in pediatric relapsed/refractory <scp>AML</scp>: Report from the therapeutic advances in childhood leukemia and lymphoma... mā Lauren Pommert, Eric S. Schafer, Jemily Malvar, Nathan Gossai, Ellynore Florendo, Kirthi Pulakanti, Katelyn E. Heimbruch, Cary Stelloh, Yueh‐Yun Chi, Richard Sposto, Sridhar Rao, Van Huynh, Patrick A. Brown, Bill H. Chang, Susan I. Colace, Michelle L. Hermiston, Kenneth Heym, Raymond J. Hutchinson, Joel A. Kaplan, Rajen Mody, Tracey O’Brien, Andrew E. Place, Peter H. Shaw, David S. Ziegler, Alan S. Wayne, Deepa Bhojwani, Michael J. Burke
I whakaputaina 2022Artigo -
5
Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium mā Yana Pikman, Sarah K. Tasian, Maria Luisa Sulis, Kristen E. Stevenson, Traci M. Blonquist, Beth Apsel Winger, Todd M. Cooper, Melinda Pauly, Kelly W. Maloney, Michael J. Burke, Patrick A. Brown, Nathan Gossai, Jennifer L. McNeer, Neerav Shukla, Peter D. Cole, Justine M. Kahn, Jing Chen, Matthew J. Barth, Jeffrey A. Magee, Lisa Gennarini, Asmani A. Adhav, Catherine Clinton, Nicole Ocasio-Martinez, Giacomo Gotti, Yuting Li, Shan Lin, Alma Imamović, Cristina E. Tognon, Tasleema Patel, Haley L. Faust, Cristina F. Contreras, Anjali Cremer, Wilian A. Cortopassi, Diego Garrido Ruiz, Matthew P. Jacobson, Neekesh V. Dharia, Angela Su, Amanda L. Robichaud, Amy Saur Conway, Katherine Tarlock, Elliot Stieglitz, Andrew E. Place, Alexandre Puissant, Stephen P. Hunger, Annette S. Kim, Neal I. Lindeman, Lia Gore, Katherine A. Janeway, Lewis B. Silverman, Jeffrey W. Tyner, Marian H. Harris, Mignon L. Loh, Kimberly Stegmaier
I whakaputaina 2021Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Internal medicine
Medicine
Oncology
Leukemia
Acute lymphocytic leukemia
Biology
Cancer
Chemotherapy
Clinical trial
Lymphoblastic Leukemia
Minimal residual disease
Algebra over a field
Astrobiology
Biochemistry
Bioinformatics
Blinatumomab
CD33
CD34
Central nervous system
Chemotherapy regimen
Cyclophosphamide
Cytarabine
DNA methylation
Decitabine
Developmental psychology
Disease
Flag (linear algebra)
Fludarabine
Gastroenterology
Gemtuzumab ozogamicin